First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors

Published on Jan 10, 2021in Journal of Clinical Oncology32.956
· DOI :10.1200/JCO.20.00596
Richard D. Baird24
Estimated H-index: 24
(University of Cambridge),
Constanza Linossi2
Estimated H-index: 2
(University of Cambridge)
+ 12 AuthorsAurelius Omlin34
Estimated H-index: 34
(HSG: University of St. Gallen)
PURPOSEA first-in-human study was performed with MP0250, a DARPin drug candidate. MP0250 specifically inhibits both vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) with...
📖 Papers frequently viewed together
1 Author (Simone P. Niclou)
2 Citations
1 Citations
#1Michael T. StumppH-Index: 21
#2Keith M. DawsonH-Index: 4
Last. H. Kaspar BinzH-Index: 22
view all 3 authors...
The DARPin® drug platform was established with a vision to expand the medical use of biologics beyond what was possible with monoclonal antibodies. It is based on naturally occurring ankyrin repeat domains that are typically building blocks of multifunctional human proteins. The platform allows for the generation of diverse, well-behaved, multifunctional drug candidates. Recent clinical data illustrate the favorable safety profile of the first DARPin® molecules tested in patients. With the posit...
12 CitationsSource
#1H. Kaspar BinzH-Index: 22
#2Talitha BakkerH-Index: 2
Last. Michael T. StumppH-Index: 21
view all 14 authors...
MP0250 is a multi-domain drug candidate currently being tested in clinical trials for the treatment of cancer. It comprises one anti-vascular endothelial growth factor-A (VEGF-A), one anti-hepatocyte growth factor (HGF), and two anti-human serum albumin (HSA) DARPin® domains within a single polypeptide chain. While there is first clinical validation of a single-domain DARPin® drug candidate, little is known about DARPin® drug candidates comprising multiple domains. Here, we show that MP0250 can ...
27 CitationsSource
#1Ulrike FiedlerH-Index: 4
#1Ulrike FiedlerH-Index: 17
Last. Keith M. DawsonH-Index: 3
view all 8 authors...
// Ulrike Fiedler 1 , Savira Ekawardhani 1 , Andreas Cornelius 1 , Pat Gilboy 1, 2 , Talitha R. Bakker 1, 3 , Ignacio Dolado 1, 4 , Michael T. Stumpp 1 and Keith M. Dawson 1 1 Molecular Partners AG, Schlieren, Switzerland 2 Horizon Pharma, Dublin, Ireland 3 Amgen (Europe) GmbH, Zug, Switzerland 4 Roche, Basel, Switzerland Correspondence to: Keith M. Dawson, email: Keywords: VEGF, HGF, serum albumin, DARPin ® , patient-derived xenograft Received: July 13, 2017 Accepted:...
11 CitationsSource
#1Tina Cascone (University of Texas MD Anderson Cancer Center)H-Index: 28
#2Li Xu (University of Texas MD Anderson Cancer Center)H-Index: 21
Last. John V. HeymachH-Index: 97
view all 25 authors...
Purpose: Resistance to VEGFR inhibitors is a major obstacle in the treatment of non–small cell lung cancer (NSCLC). We investigated the cellular mechanisms mediating resistance of NSCLCs to VEGFR tyrosine kinase inhibitors. Experimental Design: We generated murine models of human NSCLC and performed targeted inhibition studies with the VEGFR TKIs cediranib and vandetanib. We used species-specific hybridization of microarrays to compare cancer (human) and stromal (mouse) cell transcriptomes of TK...
30 CitationsSource
#1Josiah T. Ryman (UT: University of Tennessee)H-Index: 3
#2Bernd Meibohm (UT: University of Tennessee)H-Index: 50
Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications, with currently more than 40 mAbs approved by the US Food and Drug Administration, and several dozens more in clinical development. This tutorial will review major drug disposition processes relevant for mAbs, and will highlight product-specific and patient-specific factors that modulate their pharmacokinetic (PK) behavior and need to be considere...
237 CitationsSource
#1David R. SpigelH-Index: 85
#2Martin J. EdelmanH-Index: 60
Last. Tony MokH-Index: 109
view all 11 authors...
PurposeThe phase III OAM4971g study (METLung) examined the efficacy and safety of onartuzumab plus erlotinib in patients with locally advanced or metastatic non–small-cell lung cancer selected by MET immunohistochemistry whose disease had progressed after treatment with a platinum-based chemotherapy regimen.Patients and MethodsPatients were randomly assigned at a one-to-one ratio to receive onartuzumab (15 mg/kg intravenously on day 1 of each 21-day cycle) plus daily oral erlotinib 150 mg or int...
146 CitationsSource
#1Tom T. Chen (Genentech)H-Index: 12
#2Ellen Filvaroff (Genentech)H-Index: 19
Last. Avi Ashkenazi (Genentech)H-Index: 102
view all 8 authors...
Hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) drive cancer through their respective receptors, MET and VEGF receptor 2 (VEGFR2). VEGFR2 inhibits MET by promoting MET dephosphorylation. However, whether MET conversely regulates VEGFR2 remains unknown. Here we show that MET suppresses VEGFR2 protein by inducing its endoplasmic-reticulum-associated degradation (ERAD), via intracrine VEGF action. HGF–MET signaling in epithelial cancer cells promoted VEGF biosynthesis t...
7 CitationsSource
#1Arman Jahangiri (UCSF: University of California, San Francisco)H-Index: 24
#2Michael De Lay (UCSF: University of California, San Francisco)H-Index: 6
Last. Manish K. Aghi (UCSF: University of California, San Francisco)H-Index: 58
view all 17 authors...
Purpose: To identify mediators of glioblastoma antiangiogenic therapy resistance and target these mediators in xenografts. Experimental Design: We conducted microarray analysis comparing bevacizumab-resistant glioblastomas (BRG) with pretreatment tumors from the same patients. We established novel xenograft models of antiangiogenic therapy resistance to target candidate resistance mediator(s). Results: BRG microarray analysis revealed upregulation versus pretreatment of receptor tyrosine kinase ...
155 CitationsSource
#1Miroslav Dostalek (Hoffmann-La Roche)H-Index: 17
#2Iain GardnerH-Index: 22
Last. Manoranjenni ChettyH-Index: 9
view all 5 authors...
Development of monoclonal antibodies (mAbs) and their functional derivatives represents a growing segment of the development pipeline in the pharmaceutical industry. More than 25 mAbs and derivatives have been approved for a variety of therapeutic applications. In addition, around 500 mAbs and derivatives are currently in different stages of development. mAbs are considered to be large molecule therapeutics (in general, they are 2–3 orders of magnitude larger than small chemical molecule therape...
155 CitationsSource
Blocking vascular endothelial growth factor (VEGF) can promote the invasive growth of glioblastoma through a mechanism that involves MET and VEGF receptor 2.
5 CitationsSource
Cited By3
#1Aurélie Rondon (UCL: Université catholique de Louvain)H-Index: 1
#2Sohaib Mahri (UCL: Université catholique de Louvain)H-Index: 3
Last. Rita Vanbever (UCL: Université catholique de Louvain)H-Index: 34
view all 5 authors...
#1Xiaotian Zhong (Pfizer)H-Index: 6
#1Xiaotian Zhong (Pfizer)H-Index: 15
Last. Aaron M. D’Antona (Pfizer)H-Index: 5
view all 2 authors...
Recombinant protein-based biotherapeutics drugs have transformed clinical pipelines of the biopharmaceutical industry since the launch of recombinant insulin nearly four decades ago. These biologic drugs are structurally more complex than small molecules, and yet share a similar principle for rational drug discovery and development: That is to start with a pre-defined target and follow with the functional modulation with a therapeutic agent. Despite these tremendous successes, this "one target o...
1 CitationsSource
#1Marcel WalserH-Index: 1
#2Sylvia Rothenberger (UNIL: University of Lausanne)H-Index: 16
Last. Patrick AmstutzH-Index: 1
view all 54 authors...
Abstract Globally accessible preventive and therapeutic molecules against SARS-CoV-2 are urgently needed. DARPin molecules are an emerging class of novel therapeutics based on naturally occurring repeat proteins (∼15 kDa in size) and can be rapidly produced in bacteria in large quantities. Here, we report the identification of 380 DARPin molecules specifically targeting the SARS-CoV-2 spike protein selected from a naive library of 1012 DARPin molecules. Using extensive biophysical and biochemica...
10 CitationsSource